A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

March 6, 2023

Study Completion Date

July 22, 2024

Conditions

Obstructive Hypertrophic Cardiomyopathy

Interventions

DRUG

Mavacamten

Mavacamten Capsules

DRUG

Placebo

Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period

Trial Locations (1)

Peking Union Medical College Hospital, Beijing